Neuren Pharmaceuticals Limited (ASX:NEU)
Australia
· Delayed Price · Currency is AUD | Market Cap | 1.65B |
| Revenue (ttm) | 76.81M |
| Net Income (ttm) | 30.44M |
| Shares Out | 126.64M |
| EPS (ttm) | 0.23 |
| PE Ratio | 56.08 |
| Forward PE | 49.78 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 428,885 |
| Average Volume | 577,353 |
| Open | 13.50 |
| Previous Close | 13.44 |
| Day's Range | 13.03 - 13.61 |
| 52-Week Range | 8.61 - 22.99 |
| Beta | 1.74 |
| RSI | 37.15 |
| Earnings Date | Feb 27, 2026 |
About Neuren Pharmaceuticals
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develo... [Read more]
Financial Performance
In 2025, Neuren Pharmaceuticals's revenue was 76.81 million, a decrease of -64.58% compared to the previous year's 216.83 million. Earnings were 30.44 million, a decrease of -78.57%.
Financial StatementsNews
Neuren Pharmaceuticals Limited (NURPF) Discusses Share Buyback Program, Financial Position, and Development Strategy for NNZ-2591 Transcript
Neuren Pharmaceuticals Limited (NURPF) Discusses Share Buyback Program, Financial Position, and Development Strategy for NNZ-2591 Transcript